Please enter exact key words
Available Projects

Dedicated to the discovery and development of new therapies to enhance living standard and health

Home / Available Projects
Available Projects

At Protheragen, we help out-license and find co-development opportunities for drug development programs. We aspire to play a role in transforming the scientific innovations into medications, helping patients with the most challenging diseases. Our main focus is on oncology programs. Most programs that are available on the list below are at preclinical stage with great therapeutic and market potential.

If you are interested in any of the projects, please contact us for further discussion. We look forward to our collaboration.

Program Indication Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
CAR-T Therapy
GHR106-CAR-T Cancer
RP215-CAR-T Cancer
Antibody Therapy
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy
hGHR106 Cancer
RP215 Cancer
CD3XCD20 bsAb Lymphomas
Cl3hmAb Acquired immune deficiency syndrome
MUC1-Ab Acute myelocytic leukemia
LAG3-Ab Cancer
OX40-Ab Cancer
Recombinant Protein Therapy
P75NEURO Neurological diseases
P11 Type 2 diabetes
Angiocidin Acute Myeloid Leukemia
TT-173 Surgical bleeding and trauma
Oncolytic Virotherapy
RV-scFv-PDL1 Cancer
OV-FV-01 Cancer
Chemotherapy
Polyoxygenated cyclohexene compound 4 Pain
Fascin inhibitor Cancer
Mitochondrial uncoupling agent Nonalcoholic steatohepatitis
HBV capsid inhibitor Hepatitis B
KCNQ2/3 channel modulator Epilepsy
Resveratrol (micellar) Alzheimer’s disease
Inflammatory factor regulators Psoriasis
Cell Therapy
Double negative T cells Acute myelocytic leukemia
BCMA – CAR-T Multiple myeloma

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com